Wound healing activity of the human antimicrobial peptide LL37

Reinaldo Ramos1, João Pedro Silva, Ana Cristina Rodrigues

  • 1IBB, Institute of Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.

Peptides
|June 23, 2011
PubMed

Insights

The antimicrobial peptide LL37, when produced recombinantly, promotes wound healing by stimulating blood vessel formation (angiogenesis) and skin regeneration. This peptide shows potential for improving therapeutic strategies for wound repair.

Area of Science:

  • Immunology
  • Wound Healing Research
  • Biochemistry

Background:

  • Antimicrobial peptides (AMPs), like human cathelicidin LL37, are crucial for innate immunity.
  • LL37 exhibits broad antimicrobial and immunomodulatory functions and is present in various human tissues.
  • Wound healing is a complex physiological process involving inflammation and angiogenesis.

Purpose of the Study:

  • To evaluate the immunophysiological properties and wound healing potential of a newly developed recombinant LL37 peptide (P-LL37).
  • To investigate the effects of P-LL37 on macrophage activation and endothelial cell functions.
  • To assess the impact of LL37 on angiogenesis and wound regeneration in vivo.

Main Methods:

  • Development of a novel method for expressing and purifying recombinant LL37 (P-LL37).
  • In vitro assays to assess P-LL37's effect on lipopolysaccharide-activated macrophages and endothelial cell proliferation, migration, and tubule formation.
  • In vivo wound healing experiments in dexamethasone-treated mice using topical application of synthetic and recombinant LL37.

Main Results:

  • Recombinant P-LL37 retained its immunophysiological properties, neutralizing LPS-induced macrophage activation.
  • P-LL37 stimulated endothelial cell proliferation, migration, and the formation of vascular-like structures.
  • Topical LL37 significantly enhanced vascularization and re-epithelialization in mouse wound models.

Conclusions:

  • Recombinant LL37 (P-LL37) effectively preserves its biological activities.
  • LL37 plays a significant role in promoting wound regeneration by enhancing angiogenesis.
  • LL37 demonstrates therapeutic potential for improving wound healing outcomes.